Mounjaro NHS Waiting List: How Long Is It? (October 2026)

01 · The core answer

How long is the NHS waiting list for Mounjaro?

There is no single national waiting time for Mounjaro on the NHS. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years.

A phased rollout means the question is less "how long is the queue?" and more "has my group been reached yet, and does my local service have capacity?". Two people with the same BMI can face very different experiences depending on their integrated care board, their GP practice and the specialist weight-management services nearby. Our guide to NHS Mounjaro qualification covers the eligibility side in more detail.

Some regions publish their own local pathways. If you live in Scotland, our local pages on Mounjaro in NHS Tayside and Mounjaro in NHS Fife show how local arrangements can differ from the English picture.

02 · Your decision

Wait, or start privately?

Your decision comes down to whether you meet the NHS criteria now, and how much a delay matters to you. If you are in a highest-need group and your GP has opened the pathway, the NHS route may be right for you. If you do not yet qualify, or your area has no clear start date, waiting for an unknown period is a real cost in itself, and private treatment is a legitimate alternative.

Private prescribing uses the licensed criteria rather than the NHS priority groups. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.¹ A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹¹

You do not have to choose permanently. Some people join the NHS pathway and also explore private treatment while they wait. Your prescriber should know about any other weight-management treatment you are using. For the cost side, see our Mounjaro prices guide.

03 · What to do next

What to do next

Start by asking your GP practice two direct questions: has my group been opened for Mounjaro locally, and if not, is there a referral to a specialist weight-management service? Write down the answers and any reference numbers. If the answer is vague or the timescale unclear, that is useful information for deciding whether to explore the private route.

If you want to see whether you are suitable now, our free online consultation is reviewed by a GPhC-registered prescriber, and if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. You can see current options on the Mounjaro pen page, or read more about our weight loss clinic. New customers save £40 on their first order with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25).

04 · Why no single wait

Why there is no single waiting time

There is no single waiting time because the NHS is not running one national queue for Mounjaro. Access is being phased in over several years, and the phases are defined by clinical need rather than by who joined a list first. The primary-care rollout began in June 2025 with the highest-need groups first.⁶ Someone outside those groups is not necessarily sitting in a long queue; they may simply not have been reached yet.

Several local factors then shape what you experience. The first is your integrated care board, which decides how national guidance is put into practice in your area. The second is the capacity of local specialist weight-management services, which differ between regions. The third is your own GP practice, because participation and readiness are not identical everywhere. Together these explain why one person reports a short wait and another reports a very long one for what looks like the same treatment.

It also explains why headline numbers online conflict. A figure quoted for a specialist service in one borough says little about a GP-led pathway in another. When a page gives you a confident national range, ask where it came from and when it was measured.

Practically, the best use of your time is not to hunt for a headline number but to establish your own status. Are you in a group that has been reached? Has your practice started prescribing? Is there a specialist referral route? Those three answers tell you far more than any average.

05 · NHS eligibility explained

Who the NHS reaches first

The NHS is reaching the highest-need groups first, and that determines where you are likely to sit in the rollout. NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ The primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁶ Over time, the intention is for access to widen beyond those first groups, though full rollout is expected to take years.

That has a clear consequence. If you have a BMI of 40 or above and several qualifying conditions, you are in the group the rollout started with. If your BMI is lower, or you have fewer conditions, you may meet the NICE recommendation without yet being in the earliest cohort. And if your BMI is below 35, you fall outside the NICE recommendation altogether, even though you might meet the licence for private prescribing.

Ethnic background changes the picture. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight-related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.¹¹ If that applies to you, tell your GP so the adjusted thresholds can be considered when your eligibility is assessed.

Private prescribing runs on the licence rather than the NHS priority groups. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used alongside a reduced-calorie diet and increased physical activity.¹ That is a wider net than the NHS priority groups, which is why some people qualify privately well before the NHS reaches them.

Neither route is automatic. A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you, and some people are advised against treatment. Always share your full medical history and medicine list at consultation.

A practical way to use this: work out your BMI, list your weight-related conditions, and note your ethnic background if the adjustment applies. Then compare that against the groups above. If you are plainly in an early NHS group, press your GP for the local pathway. If you are not, you will need to decide whether to wait for the rollout to widen or explore regulated private treatment in the meantime. Our page on NHS Mounjaro qualification goes through this in more depth, including how the criteria are applied in practice.

Finally, remember that eligibility is not a verdict on your worth or your effort. It is a way of rationing a new treatment across a very large number of people who could benefit, and the criteria are expected to change as the rollout progresses. Revisit your position periodically rather than assuming a single "no" is permanent.

06 · Finding your place

How to find out where you are in the queue

The only reliable way to find your position is to ask the service that holds your referral. Begin with your GP practice. Ask whether a referral has been made, to which service, and on what date. Ask for any reference number, and ask who to contact for updates. If a referral has not been made, ask why, and what criteria you would need to meet.

If a referral exists, contact the service it was sent to. Many NHS services have a patient-contact or referral-management team that can confirm the referral was received and whether it has been accepted for assessment. Keep a short log of each contact: the date, the person you spoke to and what you were told. A written record makes it far easier to escalate if your referral seems stuck.

Check that your details are correct. A surprising number of delays come from out-of-date phone numbers, addresses or email addresses, which means letters and calls never reach the patient. Confirm with your practice that the contact information on your record is current, and ask how the service will reach you, whether by post, text or phone.

It also helps to understand what the rollout means for you. The NHS primary-care rollout began in June 2025 with the highest-need groups first, and full rollout is expected to take years.⁶ If your group is not yet being reached, you may not be on any list at all, and the honest answer from your practice may be that there is nothing to track yet. That is frustrating, but it is more useful to know than to wait for a letter that is not coming.

Some practical questions to put to your GP:

• Has Mounjaro been opened to my clinical group in this area?
• If not, is there a specialist weight-management referral I can be considered for?
• What would change my priority, such as a new diagnosis or a change in BMI?
• When will my case be reviewed again?

If the answers leave you without a timescale, you can reasonably weigh up other options. Our weight loss clinic page sets out how private treatment works, and you do not need to abandon your NHS referral to explore it. Just be open with each clinician about what you are using, so that your care stays coordinated and safe.

One more tip: if you are referred to a service and then hear nothing for a long time, ask politely whether it is normal for your area, and whether there is a way to confirm your place. Services are generally busy rather than unhelpful, and a clear, courteous request usually gets a clearer response than a general complaint.

07 · Speeding up a referral

Can you speed up an NHS referral?

You cannot jump the queue, but you can make sure nothing is slowing your referral unnecessarily. The aim is to remove avoidable delays, not to claim priority you do not have. Clinical need decides priority, so the most effective step is making sure your GP has a full and accurate picture of your health.

Start by booking a dedicated appointment to discuss weight management rather than raising it at the end of another visit. Bring your BMI, a list of weight-related conditions you have been diagnosed with, and your current medicines. NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition, so being clear about which conditions you have matters.⁴ If you have a condition that has not been formally recorded, ask your GP whether it should be.

Mention your ethnic background if relevant, because clinical thresholds are usually reduced for some groups, and that can affect whether you meet the criteria sooner. Also tell your GP if your health has changed, for example a new diagnosis or a worsening condition, since that can change how urgent your case appears.

Can a GP fast-track a referral? A GP can mark a referral as more urgent where there is clinical justification, but that decision rests on your health needs rather than on how long you have waited or how much you want treatment. It is reasonable to ask whether anything in your history would support a higher priority, and to accept the answer. Pressing for a fast track without clinical grounds tends to waste appointment time and can strain a relationship you need.

Why might a referral be rejected? Common reasons include the person not meeting the criteria for that service, missing information, or the referral being sent to the wrong pathway. If yours is rejected, ask for the reason in writing and ask what would make a resubmission successful. Sometimes the fix is simply additional detail from your records.

Meanwhile, keep your own records tidy. Note the dates of appointments, the names of clinicians and the outcome of each conversation. If something goes wrong, those notes make it much easier to raise a concern with the practice or the service, and they help any new clinician you see understand your history.

If, after doing all this, the timescale is still unclear, it is sensible to consider whether regulated private treatment suits you. It is not a way of getting ahead of others, but an alternative route for adults who meet the licensed criteria and who prefer not to wait for an uncertain date.

08 · Private route and cost

The private route: how it works and what it costs

The private route uses the licensed criteria and a prescriber review, and it can start without waiting for the NHS rollout to reach you. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition.¹ A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹¹

Ordering from us works in four steps. First, a free online consultation: a short health questionnaire with no charge and no obligation. Second, a review by a GPhC-registered prescriber. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Third, dispensing by our registered pharmacy, with same-day dispatch when ordered by 3pm. Fourth, free next-day tracked delivery in temperature-controlled, discreet packaging. Saturday delivery is £14.99.

We supply Mounjaro through official LillyDirect supply, direct from Eli Lilly's UK distribution, with genuine KwikPens, and all six doses are in stock. Our GPhC registration number is 9012878. Needles, a sharps bin and injection guidance are included with every order, and ongoing monthly reviews, dose-titration and follow-up assessments are carried out by the prescribing team. Repeat orders re-check suitability, and nothing ships automatically.

On cost, the standard price of the 2.5mg starter pen is £169.99. Your first 2.5mg pen costs £129.99 with code FIRST40, and every later order is £25 off the standard price (code DOSE25). Everyone starts on 2.5mg, then moves up in steps; if you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices before discounts. A first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg, again at standard prices. The price shown is the price paid; the consultation is free and there are no hidden fees. Prices checked 11 October 2026.

Payment is by Visa or Mastercard, Klarna or pay-monthly options, with no subscription lock-in. For a full dose-by-dose breakdown, see our Mounjaro prices page or the new Mounjaro price list.

Whichever provider you consider, check that it is a registered pharmacy; you can verify ours on the GPhC register.

You can start with the Mounjaro pen page, which shows current prices and the consultation.

09 · What to expect

What to expect once you start

Weight loss on Mounjaro is gradual by design, whether you start through the NHS or privately. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month. Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.²

Everyone starts on 2.5mg once a week. This starting dose is about letting your body adjust, not about weight loss itself. After at least 4 weeks the dose increases to 5mg, and can then step up by 2.5mg at a minimum of 4-week intervals (7.5mg, 10mg, 12.5mg) up to a maximum of 15mg weekly, depending on how you respond and tolerate it. Many people settle at a maintenance dose of 5mg, 10mg or 15mg; higher is not automatically better, and your prescriber will guide the right pace.¹

The headline trial result is worth knowing, with the right caveats. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone. These are trial averages; individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at this stage are modest compared with the headline figures. A sensible three-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.²

The first weeks differ widely between people. Some notice appetite change and early loss in the first week, others feel little until a higher dose, and both are normal. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.¹³

Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹

This matters for the waiting question because it shows that a delay of a few weeks at the start is small compared with the months of gradual change that follow. It is more important to start with a safe, well-supported plan than to chase speed. For more on tolerability, see our list of Mounjaro side effects.

10 · Safety and suitability

Safety: who should not take Mounjaro

Mounjaro is not suitable for everyone, and that applies on the NHS and privately alike. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. Always share your full medical history and medicine list during consultation.¹¹³

There is also a thyroid precaution. In rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials. As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2, as they will weigh this in your assessment. Routine thyroid monitoring is not required for most people.¹

These are the reasons a prescriber review matters. Our consultation is reviewed by a GPhC-registered prescriber, and if an order is unsuitable it is refunded automatically. If you are on the NHS pathway, the same questions will be asked by your clinician. Neither route is a formality, and an honest, complete history protects you.

Beware of anyone offering to supply Mounjaro without a consultation or prescription. Mounjaro is a prescription-only medicine, and counterfeit products are a recognised risk, which is why the MHRA publishes alerts.⁷ Buy only from a registered UK pharmacy, and check the register. A very low price from an unknown seller, or one that skips clinical review, is a warning sign rather than a bargain.

If you experience a side effect, tell your prescriber, and you can also report it through the MHRA Yellow Card scheme.¹⁹ Reporting helps regulators monitor safety for everyone. Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. For any new or lasting symptom, tell your prescriber.

Finally, treatment is used alongside a reduced-calorie diet and increased physical activity, and individual results vary. You can read the full tolerability picture in our full list of Mounjaro side effects.

11 · While you wait

What to do while you wait

Waiting does not have to mean standing still, because the habits that support treatment are worth building now. Mounjaro is used alongside a reduced-calorie diet and increased physical activity, not instead of them.¹ If you establish a steady routine of regular meals, more daily movement and good sleep before you start, you will be better placed whenever treatment begins, and these changes carry benefits whatever happens with your referral.

Keep your GP informed. If your health changes, for example a new diagnosis or a change in medicines, tell them, as it may affect your eligibility or priority. Also keep a note of your weight and measurements over time. A simple trend is more useful to a clinician than a single reading, and it gives you a baseline for judging progress later. Our free companion app, GLPTrackr, is available for iOS and Android if you want a place to log your journey.

Other options exist, and your prescriber can advise on them. Orlistat is one alternative some people consider; our page on orlistat with no waiting list explains how it is prescribed privately. Figures for its effect vary, so your prescriber can advise on whether it suits you. It works differently from Mounjaro and is not a like-for-like substitute.

Wegovy (semaglutide) is another licensed weight-management medicine. Its pens are 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, with titration stepping up after at least 4 weeks and reaching the 2.4mg maintenance dose from week 17. Availability can change, so check at the time of order. NHS access to Wegovy runs through specialist weight-management services; ask your GP. Tirzepatide has a dual action on two gut-hormone receptors, GIP and GLP-1, which distinguishes it from single-action medicines such as semaglutide.¹

SURMOUNT-5 was the first large head-to-head trial of tirzepatide and semaglutide for weight loss.¹⁵ It would be misleading to compare numbers from different trials as though they were head to head.

Be wary of products marketed as natural alternatives. Low-cost supplements are available cheaply without assessment, but they come with no clinical oversight, and dosing is not standardised. Dramatic weight-loss claims on such products deserve scepticism, and they should not be treated as equivalent to licensed medicines.

If you decide to start privately, you can see the Mounjaro pen page, and your NHS referral can stay in place; simply tell each clinician what you are taking. If you later become eligible and want to move to NHS care, discuss the transition with your GP so that your dose and history carry across smoothly.

12 · Injecting and storage

Practical basics if you start treatment

Mounjaro is injected under the skin once a week, and the practical routine is simple once you have settled in. It is injected subcutaneously on the same day each week, at any time of day, with or without food. Licensed injection sites are the stomach area (at least 5cm from the belly button), the front of the thigh, or the back of the upper arm if someone else gives the injection. Rotate the site with each dose. Each KwikPen contains four weekly doses.¹

There is no best time of day, as Mounjaro works the same morning or evening, with or without food. What matters is the same day each week. Pick a day and time you will remember; many people choose a weekend morning so early side effects fall on days off. You can change your weekly injection day if needed, as long as at least 3 days (72 hours) have passed since your last dose.¹³

Follow the pen's instructions each time.

If you miss a dose, take it as soon as you can within 4 days (96 hours) of the scheduled time, then carry on with your usual day. If more than 4 days have passed, skip the missed dose entirely and take the next one on your normal day; never take two doses within 3 days of each other.¹

For storage, keep Mounjaro pens in a fridge at 2–8°C and never freeze them. Once in use, a pen can be kept out of the fridge not above 30°C for up to 30 days, which is useful for short trips, after which it should be discarded. Keep the pen cap on to protect it from light, and never use a pen that has been frozen.¹¹³

You can fly with Mounjaro. Carry pens in hand luggage, because hold luggage can fall below freezing, ideally in a cool bag with the prescription label or a copy of your prescription. Unopened pens should be kept in the fridge and keep until the expiry date printed on the box. If an unopened pen has been out of the fridge, check with the pharmacy before using it rather than relying on a remembered day limit.

If you stop, tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹